We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Events

26 Oct 2026 - 29 Oct 2026
16 Nov 2026 - 19 Nov 2026

Glucosamine Equal to Placebo in Treating Lower Back Pain

By HospiMedica International staff writers
Posted on 19 Jul 2010
A new study has found that glucosamine is no better than placebo at reducing pain-related disability in people suffering from lower back pain (LBP) due to degenerative lumbar osteoarthritis (OA).

Researchers at Oslo University Hospital (OUH; Norway) conducted a double blind, randomized, placebo-controlled trial with 250 participants aged over 25, who were recruited from outpatients attending the OUH outpatient clinic who had been experiencing LBP for more than six months, together with degenerative lumbar OA. More...
The participants were randomized to two groups of 125 patients; one group took 1,500 mg of glucosamine supplement every day for 6 months, and the other group took a placebo. The patients underwent assessment at baseline, and then at fixed time points during the six month period, and again at one year. All patients completed the Roland Morris Disability Questionnaire (RMDQ) about their quality of life, level of disability, and levels of pain experienced during rest and activity.

The researchers found that at baseline, mean RMDQ scores were 9.2 for the glucosamine and 9.7 for the placebo group. At 6 months, the mean RMDQ score was the same for both groups; at one year, the mean RMDQ scores were 4.8 for glucosamine and 5.5 for the placebo group. No statistically significant difference in change between groups in RMDQ, LBP, or quality of life was found when assessed after the 6-month intervention period and at one year. Mild adverse events were reported in 40 patients in the glucosamine group and 46 in the placebo group. The study was published in the July 7, 2010, issue of the Journal of the American Medical Association (JAMA).

"Among patients with chronic LBP and degenerative lumbar OA, 6-month treatment with oral glucosamine compared with placebo did not result in reduced pain-related disability after the 6-month intervention and after 1-year follow-up,” concluded lead author Philip Wilkens, M.Chiro., and colleagues of the department of orthopedics.

Glucosamine is an amino sugar and a prominent precursor in the biochemical synthesis of glycosylated proteins and lipids, and is one of the most common nonvitamin, nonmineral, dietary supplements used by adults. Glucosamine is part of the structure of the polysaccharides chitosan and chitin, which compose the exoskeletons of crustaceans and other arthropods, cell walls in fungi, and many higher organisms. It is produced commercially by the hydrolysis of crustacean exoskeletons or, less commonly by fermentation of a grain such as corn or wheat.

Related Links:

Oslo University Hospital



Gold Member
12-Channel ECG
CM1200B
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Wound Irrigation Solution
Prontosan®
Breast Imaging Monitor
Barco Coronis Onelook MDMC-32133 32MP
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Half-matched bone marrow transplant expands access to curative treatment for children and young adults with severe aplastic anemia. (Photo courtes of Margarita Dionysiou using Bio Render)

Half-Matched Family Donors Could Expand Transplant Access for Severe Aplastic Anemia

Severe aplastic anemia is a rare, life-threatening disorder in which the bone marrow fails to produce enough healthy blood cells, leaving children and young adults vulnerable to anemia, infection, and bleeding.... Read more

Patient Care

view channel
Image: Researchers evaluated the Omni 128 cm long-axial field-of-view PET/CT system, which captures more of the body and radiotracer signal at once, potentially enabling shorter scans. (Photo courtesy of GE HealthCare)

Total-Body PET/CT Scanner Enables One-Minute Diagnostic-Quality Cancer Imaging

Positron emission tomography/computed tomography (PET/CT) combines radiotracer-based functional imaging with anatomical detail to diagnose, stage, and monitor cancer. Conventional scanners image the body... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: Steris is expanding its healthcare consumables portfolio through an agreement to acquire Xodus Medical, a surgical products business focused on patient and operating room staff safety.

Steris to Expand Surgical Safety Portfolio With $2.1 Billion Xodus Medical Deal

Steris has signed a definitive agreement to acquire Xodus Medical, a specialty surgical products business based in Pennsylvania, for $2.1 billion at closing. The acquisition will expand Steris’s healthcare... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.